Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
Rago A, Grammatico S, Za T, Levi A, Mecarocci S, Siniscalchi A, De Rosa L, Felici S, Bongarzoni V, Piccioni AL, La Verde G, Pisani F, Franceschini L, Paviglianiti AL, Caravita T, Petrucci MT, De Stefano V, Cimino G; Multiple Myeloma GIMEMA-Latium Region Working Group. Rago A, et al. Among authors: la verde g. Cancer. 2012 Nov 15;118(22):5544-9. doi: 10.1002/cncr.27657. Epub 2012 Jul 11. Cancer. 2012. PMID: 22786730 Free article.
Coexistent multiple myeloma and myelofibrosis.
Pulsoni A, Bianco P, La Verde G, Mecarocci S, Petrucci MT, Torromeo C, Avvisati G. Pulsoni A, et al. Among authors: la verde g. Leuk Lymphoma. 1993 Jul;10(4-5):401-3. doi: 10.3109/10428199309148567. Leuk Lymphoma. 1993. PMID: 8220140
[Therapy of multiple myeloma].
La Verde G, Pulsoni A, Petrucci MT, Mandelli F. La Verde G, et al. Recenti Prog Med. 1997 Apr;88(4):186-93. Recenti Prog Med. 1997. PMID: 9206817 Review. Italian.
Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma.
Petrucci MT, Avvisati G, La Verde G, De Fabritiis P, Ribersani M, Palumbo G, De Felice L, Rusignuolo A, Simone F, Meloni G, Mandelli F. Petrucci MT, et al. Among authors: la verde g. Acta Haematol. 2003;109(4):184-8. doi: 10.1159/000070967. Acta Haematol. 2003. PMID: 12853690
IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy.
Pisani F, Petrucci MT, Giannarelli D, Bongarzoni V, Montanaro M, De Stefano V, La Verde G, Gentilini F, Levi A, Za T, Moscetti A, Annino L, Petti MC; Multiple Myeloma GIMEMA-Latium Region Working Group, Italy. Pisani F, et al. Among authors: la verde g. J Exp Clin Cancer Res. 2012 Mar 1;31(1):17. doi: 10.1186/1756-9966-31-17. J Exp Clin Cancer Res. 2012. PMID: 22381082 Free PMC article.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Cavo M, et al. Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12. Blood. 2012. PMID: 22498745 Free article. Clinical Trial.
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F, Siniscalchi A, Rizzo M, Za T, Antolino G, Coppetelli U, Piciocchi A, Andriani A, Annibali O, De Rosa L, Cimino G, La Verde G, De Stefano V, Cantonetti M, di Toritto TC, Petrucci MT. Vozella F, et al. Among authors: la verde g. Ann Hematol. 2021 Apr;100(4):1059-1063. doi: 10.1007/s00277-020-04374-y. Epub 2021 Feb 2. Ann Hematol. 2021. PMID: 33528611
62 results